Form 4: Jaguar Health Director Anula Jayasuriya Acquires 21,000 Stock Options

Anula Jayasuriya, a director of Jaguar Health, Inc., was granted 21,000 stock options on October 8, 2024, according to a Form 4 filing with the SEC.

Summary

• Anula Jayasuriya, a director at Jaguar Health, Inc., acquired 21,000 stock options on October 8, 2024.
• The options were granted under the company's 2014 Stock Incentive Plan.
• The exercise price of the options is $1.29.
• The options will vest 100% on the first anniversary of the grant date, contingent upon continued service on the board of directors.
• The options expire on October 8, 2034.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing regarding stock option grants. It's neutral in tone and doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant is relatively small, suggesting it is more of a retention incentive than a major wealth creation event for the director.
• Comparable companies such as Catalyst Pharmaceuticals and Agenus also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder value if the director's performance improves as a result of the incentive.

Key Dates

Keywords

stock options, Form 4, director, Jaguar Health, JAGX, beneficial ownership, insider trading